ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO929

Antibody Response After COVID-19 Vaccination in CKD and Kidney Transplant Patients

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Author

  • Trakarnvanich, Thananda, Faculty of Medicine Vajira Hospital, Bangkok, Thailand
Background

Vaccination of patients with chronic kidney disease (CKD) and kidney transplants (KTs) may achieve a less robust immune response. Understanding such immune responses is crucial for guiding current and future vaccine dosing strategies.

Methods

This prospective, observational study estimated the immunogenicity of humoral and cellular responses of two SARS-CoV-2 vaccines in different patient groups with CKD compared to controls. Secondary outcomes were adverse events after vaccination and the incidence of COVID-19 breakthrough infection, including illness severity.

Results

In total, 212 patients received ChAdOx1 nCoV-19 (89.62%) or inactivated vaccines (10.38%). The antibody response against the S protein was analyzed at T0 (before the first injection), T1 (before the second injection), and T2 (12 weeks after the second injection). Seroconversion occurred in 92.31% of controls at T2 and in 100% of CKD, 42.86% of KT, 80.18% of hemodialysis (HD), and 0% of continuous ambulatory peritoneal dialysis (CAPD) patients at T2 of ChAdOx1 nCoV-19 vaccine. Neutralizing antibody levels were above the protective level at T2 in each group.The KT group had the lowest neutralizing antibody and IFNγ .Blood groups O and vaccine type were associated with good immunological responses. After the first dose, 14 individuals(6.6%) out of the total population experienced breakthrough COVID-19 infection.

Conclusion

Immunity in patients with CKD and HD after vaccination was strong and comparable to that of healthy controls. Our study suggests that a single dose of the vaccine is not efficacious and delays may result in breakthrough infection.Some blood group and type of vaccine can affect the immune response.

Funding

  • Government Support – Non-U.S.